According to this analysis by Josh Farkas associate professor of Pulmonary and Critical Care Medicine at the University of Vermont, on the Chinese study,
https://emcrit.org/pulmcrit/hydroxychloroquine-fail/
It says:
The study has major limitations, for example:
* Lack of blinding or placebo control.
* Performance of the study by a contract research organization, rather than directly by the investigators.
* Early termination due to recruitment problems and the impression of benefit (which may have led to under-powering).
* Relatively long delay between symptom onset and treatment initiation (16-17 days).
The last limitation is the one that kills the result of the study.
thanks for that info- yep- that last one is a doosey-
many docs though are touting it’s usage even in late stages, and a lot of anecdotal stories about people on brink making miraculous recoveries when given the drugs- but I’m sure some don’t make it in late stages-
[[”Nonetheless,” he says, “this study currently represents the highest available quality of evidence regarding hydroxychloroquine.”]]
BS- man6 studies and trials show just the opposite- and were more thorough than their study- evidently-
> The study has major limitations, for example:...
Other major limitation:
The study is from CHINA.